Association between Industry Payments and Anti-vascular Endothelial Growth Factor Use in Medicare Beneficiaries

Industry payments to ophthalmologists who perform intravitreal injections were associated with higher odds of ranibizumab and aflibercept use, and lower odds of bevacizumab use. These findings reflect an association, not a cause-and-effect relationship.